United kingdom first to grant licence for teva's ophthalmology biosimilar ongavia (ranibizumab)▼

Amsterdam--(business wire)--teva pharmaceutical industries ltd welcomes the uk medicines & healthcare regulatory agency (mhra) decision to grant a licence for ongavia®, a biosimilar to lucentis® (ranibizumab ), an eye injection. the united kingdom is the first country in europe to authorize commercialization of ongavia® for the treatment of neovascular (wet) age-related macular degeneration (“amd”). ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oe
TEVA Ratings Summary
TEVA Quant Ranking